MHRA Class 4 Medicines Defect Notification: Vesomni 6 mg/0.4 mg modified release tablets (Quadrant Pharmaceuticals Limited)

MHRA Class 4 Medicines Defect Notification: Vesomni 6 mg/0.4 mg modified release tablets (Quadrant Pharmaceuticals Limited)

Drug alert number: EL(26)A/16

Date issued: 26 March 2026

Quadrant Pharmaceuticals Limited have informed the MHRA that their parallel imported packs of Vesomni 6 mg/0.4 mg modified release tablets have been printed with the incorrect barcode/GTIN on the carton.

DMRC reference number: DMRC-38793027

Marketing Authorisation Holder: Quadrant Pharmaceuticals Limited

Medicine Details

Product name: Vesomni 6 mg/0.4 mg modified release tablets

PLPI: 20774/2577

Active ingredient: solifenacin succinate, tamsulosin hydrochloride

SNOMED code: 11980501000001100

GTIN: 5061052110579

Affected Lot Batch Numbers

Background

Quadrant Pharmaceuticals Limited have informed the MHRA that their parallel imported packs of Vesomni 6 mg/0.4 mg modified release tablets have been printed with the incorrect barcode/GTIN on the carton. The GTIN printed on the affected packs is the GTIN for their parallel imported Solaraze 3% Gel 2 x 25 g packs (containing diclofenac). The other product details on the carton, including the name, strength and pharmaceutical form of the medicine are correct. The quality of the tablets is not impacted by the labelling defect.

Only the specified batches of imported packs are affected.

Advice for healthcare professionals

Do not to use this batch of medicine in robotic or automated dispensing or stocking systems. Carry out manual dispensing and stocking, as appropriate. Product quality of the Vesomni 6 mg/0.4 mg modified release tablets is not impacted by this issue, therefore the affected batches are not being recalled.

View the full alert here.

Advice for Patients

No action is needed from patients, continue to take medication from these batches of tablets. The actions will be controlled by the healthcare professionals who prescribe or dispense the medication.

Patients who experience adverse reactions or have any questions about their medication should seek medical attention. Any suspected adverse reactions should also be reported via the MHRA Yellow Card scheme.

Additional information

For all medical information enquiries and information on this product, please email maxearnqa@maxearn.co.uk or telephone 01204 471269.

For stock control enquiries please email maxearnqa@maxearn.co.uk or telephone 01204 471269.

The post MHRA Class 4 Medicines Defect Notification: Vesomni 6 mg/0.4 mg modified release tablets (Quadrant Pharmaceuticals Limited) appeared first on Community Pharmacy England.